325 related articles for article (PubMed ID: 31623643)
1. Immunotherapy of brain metastases: breaking a "dogma".
Di Giacomo AM; Valente M; Cerase A; Lofiego MF; Piazzini F; Calabrò L; Gambale E; Covre A; Maio M
J Exp Clin Cancer Res; 2019 Oct; 38(1):419. PubMed ID: 31623643
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
3. Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
Grätz V; Langan EA; Neumann A; Zillikens D; Terheyden P
Melanoma Res; 2019 Oct; 29(5):516-521. PubMed ID: 30870272
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy targeting immune check-point(s) in brain metastases.
Di Giacomo AM; Valente M; Covre A; Danielli R; Maio M
Cytokine Growth Factor Rev; 2017 Aug; 36():33-38. PubMed ID: 28736183
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
[TBL] [Abstract][Full Text] [Related]
8. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
9. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
15. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
16. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
17. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]